secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001493152-24-004927
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma acquires PSMA-Boron theranostic asset; engages new IR firm
-------------------------------------------------------------------------

- Upfront $10k each and milestone payments up to $40k each to inventors; 3% royalty on net revenues.
- PSMA-Boron is a theranostic agent for diagnosis, staging, and therapy of prostate cancer.
- Company engaged John Columbia Inc. to supplement existing IR firm Lytham Partners.
- Asset purchase agreement executed Jan 30, 2024; inventors assigned all rights to company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224004927/0001493152-24-004927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224004927/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-004927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer